It is my great pleasure to welcome the first issue of Ultrasound International Open in 2022 even though 2023 is approaching.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886500 | PMC |
| http://dx.doi.org/10.1055/a-1834-2542 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in human organoids-on-chips in biomedical research.
Life Med
February 2023
Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
Organoids-on-chips is opening up new frontier of research in biomedical field by combining organoids and organs-on-chips technology. The integrative technology offers great opportunities to maximize the potentials of organoids with higher fidelity, thus building advanced organ model systems in a physiologically relevant manner. In this review, we highlight the key features of organoids-on-chips and how this integrative technology could be used to build organoids in higher fidelity under controlled cellular microenvironment.
View Article and Find Full Text PDFEvaluating the risk of mild serotonin syndrome in primary care: a retrospective case series of patients with treatment-resistant depression.
AME Case Rep
November 2024
Faculty of Medicine, Imperial College London, London, UK.
Background: Serotonin syndrome is an adverse drug reaction characterised by the excess of serotonin activity in the central nervous system. It is a condition of great concern in primary care where some patients, usually with treatment-resistant depression, get treatment with multiple serotonergic agents.
Case Description: This retrospective case series looked at 20 primary care patients with treatment-resistant depression who developed mild serotonin syndrome after starting a second antidepressant.
Cognivue characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.
J Alzheimers Dis
January 2025
Cognivue, Inc., Victor, NY, USA.
Background: Cognivue is an FDA-cleared computerized cognitive test to screen for cognitive impairment included in the Bio-Hermes Study to test blood-based and digital biomarkers' ability to screen for mild cognitive impairment (MCI) and Alzheimer's disease (AD). A subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but no current assessment can identify these individuals in the absence of expensive biomarkers.
Objective: We examined differences in Cognivue performance between amyloid positive and amyloid negative individuals and whether Cognivue could differentiate True Controls (cognitively normal/amyloid negative), Preclinical AD (cognitively normal/amyloid positive), and MCI due to AD (MCI-AD, cognitively impaired/amyloid positive).
Special Issue: Insight in the Application of Rehabilitation Devices in Neurological Disease.
Brain Sci
January 2025
Behavioral and Robotic Neurorehab Unit, IRCCS Centro Neurolesi "Bonino Pulejo", 98123 Messina, Italy.
It was a great pleasure to be the guest editor for the Special Issue on understanding the use of rehabilitation devices in neurological diseases [...
View Article and Find Full Text PDFHip Arthroscopy and Its Impact on Performance in National Hockey League Players Using Team-Based Advanced Performance Statistics.
Orthop J Sports Med
January 2025
Twin Cities Orthopedics, Edina, Minnesota, USA.
Background: Ice hockey players have a high rate of hip pathology, which can lead to hip arthroscopy. Previous studies have not utilized team-based advanced performance statistics in the setting of hip arthroscopy in National Hockey League (NHL) players.
Purpose/hypothesis: The purpose of this study was to use team-based advanced performance statistics to evaluate postoperative performance after hip arthroscopy in NHL players in comparison with their preoperative performance and matched controls of uninjured skaters.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!